Titan’s Probuphine gains more media attention

The Herald Bulletin of Madison County, Indiana has published a feature about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for the treatment of opioid addiction.

The article highlights Probuphine's ability to provide around-the-clock, stable levels of buprenorphine for six months, significantly benefiting patients and clinicians by assisting with compliance and by decreasing the possibility of abuse or diversion.

The article can be viewed here.